Pacer Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.3M | Buy |
169,230
+139,609
| +471% | +$18.5M | 0.06% | 289 |
|
|
2025
Q4 | $4.2M | Buy |
29,621
+16,257
| +122% | +$2.36M | 0.01% | 772 |
|
|
2025
Q3 | $1.88M | Buy |
+13,364
| New | +$1.81M | ﹤0.01% | 1121 |
|
|
2025
Q2 | – | Sell |
-14,940
| Closed | -$1.65M | – | 3530 |
|
|
2025
Q1 | $1.65M | Sell |
14,940
-16,897
| -53% | -$2.14M | ﹤0.01% | 1027 |
|
|
2024
Q4 | $4.35M | Buy |
31,837
+3,044
| +11% | +$376K | 0.01% | 663 |
|
|
2024
Q3 | $3.32M | Sell |
28,793
-3,097
| -10% | -$425K | 0.01% | 771 |
|
|
2024
Q2 | $4.39M | Buy |
31,890
+13,782
| +76% | +$1.89M | 0.01% | 622 |
|
|
2024
Q1 | $2.5M | Buy |
18,108
+3,500
| +24% | +$478K | 0.01% | 772 |
|
|
2023
Q4 | $1.92M | Buy |
14,608
+6,450
| +79% | +$742K | 0.01% | 799 |
|
|
2023
Q3 | $918K | Sell |
8,158
-12,344
| -60% | -$1.3M | ﹤0.01% | 899 |
|
|
2023
Q2 | $1.93M | Buy |
+20,502
| New | +$2M | 0.01% | 746 |
|
|
2023
Q1 | – | Sell |
-18,422
| Closed | -$2.2M | – | 2314 |
|
|
2022
Q4 | $2.2M | Buy |
18,422
+14,218
| +338% | +$1.67M | 0.01% | 551 |
|
|
2022
Q3 | $447K | Buy |
+4,204
| New | +$427K | ﹤0.01% | 859 |
|
|
2022
Q1 | – | Sell |
-12,247
| Closed | -$1.04M | – | 2457 |
|
|
2021
Q4 | $1.04M | Buy |
12,247
+2,581
| +27% | +$237K | 0.01% | 1173 |
|
|
2021
Q3 | $927K | Sell |
9,666
-234
| -2% | -$22.1K | 0.01% | 910 |
|
|
2021
Q2 | $963K | Buy |
9,900
+9,101
| +1,139% | +$872K | 0.01% | 868 |
|
|
2021
Q1 | $78K | Sell |
799
-656
| -45% | -$68.8K | ﹤0.01% | 1327 |
|
|
2020
Q4 | $139K | Buy |
1,455
+542
| +59% | +$52.4K | ﹤0.01% | 1299 |
|
|
2020
Q3 | $88K | Buy |
+913
| New | +$106K | ﹤0.01% | 1269 |
|
|
2018
Q4 | – | Sell |
-2,661
| Closed | -$327K | – | 866 |
|
|
2018
Q3 | $327K | Buy |
+2,661
| New | +$302K | 0.01% | 939 |
|
|
2018
Q1 | – | Sell |
-1,925
| Closed | -$149K | – | 1096 |
|
|
2017
Q4 | $149K | Sell |
1,925
-8,707
| -82% | -$594K | 0.01% | 925 |
|
|
2017
Q3 | $652K | Sell |
10,632
-345
| -3% | -$18.2K | 0.06% | 519 |
|
|
2017
Q2 | $505K | Buy |
10,977
+1,167
| +12% | +$56.6K | 0.05% | 599 |
|
|
2017
Q1 | $425K | Buy |
9,810
+1,780
| +22% | +$76.3K | 0.05% | 588 |
|
|
2016
Q4 | $311K | Buy |
8,030
+472
| +6% | +$21.4K | 0.04% | 667 |
|
|
2016
Q3 | $383K | Buy |
7,558
+1,302
| +21% | +$64.8K | 0.06% | 480 |
|
|
2016
Q2 | $284K | Buy |
+6,256
| New | +$288K | 0.04% | 599 |
|
Other funds holding NBIX
VPM
VCM
Pacer Advisors's NBIX Position: Q1 2026 in Review
Pacer Advisors increased its Neurocrine Biosciences (NBIX) stake by 471% in Q1 2026, buying an estimated $18.5M and bringing the position to 169,230 shares worth $22.3M. The position accounts for 0.06% of the portfolio, ranked #289.
Pacer Advisors first reported a position in NBIX in Q2 2016 and has held it in 27 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Pacer Advisors held 169,230 shares of Neurocrine Biosciences worth $22.3M as of Q1 2026.
- Pacer Advisors bought 139,609 Neurocrine Biosciences shares in Q1 2026, an estimated $18.5M.
- Neurocrine Biosciences made up 0.06% of Pacer Advisors's portfolio in Q1 2026, its #289 holding.
- Pacer Advisors first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 27 quarters since.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.